Abstract
Current therapeutic options for patients with progressive thyroid cancer are relatively ineffective. There is a clear need to develop new alternatives for the management of this malignancy. As the knowledge of thyroid cancer biology advances, a large number of genetic events, molecular abnormalities, alterations of signaling pathways have been identified in the development and progression of thyroid neoplasms, and the potential exists to develop compounds targeted to treat thyroid cancers that do not respond to traditional therapy. In this review we described the recent development in thyroid carcinogenesis where the potential and novel intervention may exist. The discussion of thyroid carcinogenesis was integrated with exploitation of anti-thyroid agents that are currently either in clinical trials or in preclinical development for thyroid cancer.
Keywords: Thyroid cancer, carcinogenesis, therapy
Current Drug Targets
Title: Carcinogenesis and Therapeutic Strategies in Thyroid Cancer
Volume: 11 Issue: 6
Author(s): Zhi-Min Liu, Ting-Ting Wu, C. Andrew van Hasselt and George G. Chen
Affiliation:
Keywords: Thyroid cancer, carcinogenesis, therapy
Abstract: Current therapeutic options for patients with progressive thyroid cancer are relatively ineffective. There is a clear need to develop new alternatives for the management of this malignancy. As the knowledge of thyroid cancer biology advances, a large number of genetic events, molecular abnormalities, alterations of signaling pathways have been identified in the development and progression of thyroid neoplasms, and the potential exists to develop compounds targeted to treat thyroid cancers that do not respond to traditional therapy. In this review we described the recent development in thyroid carcinogenesis where the potential and novel intervention may exist. The discussion of thyroid carcinogenesis was integrated with exploitation of anti-thyroid agents that are currently either in clinical trials or in preclinical development for thyroid cancer.
Export Options
About this article
Cite this article as:
Liu Zhi-Min, Wu Ting-Ting, Andrew van Hasselt C. and G. Chen George, Carcinogenesis and Therapeutic Strategies in Thyroid Cancer, Current Drug Targets 2010; 11 (6) . https://dx.doi.org/10.2174/138945010791170897
DOI https://dx.doi.org/10.2174/138945010791170897 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Impact of Traditional Chinese Medicine on Mitophagy in Disease Models
Current Pharmaceutical Design Thyroglobulin Autoantibodies as Surrogate Biomarkers in the Management of Patients with Differentiated Thyroid Carcinoma
Current Medicinal Chemistry Passive Smoking, Asthma and Allergy in Children
Inflammation & Allergy - Drug Targets (Discontinued) Interleukin-26, a Highly Cationic T-Cell Cytokine Targeting Epithelial Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer
Mini-Reviews in Medicinal Chemistry Genetic Alterations in Differentiated Thyroid Cancers
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Imaging with Nucleic Acid Aptamers
Current Medicinal Chemistry Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Current Genomics Clinical Thiazolidinediones as PPARγ Ligands with the Potential for the Prevention of Cardiovascular Disease in Diabetes
Current Diabetes Reviews The Intermediate Enzymes of Isoprenoid Metabolism as Anticancer Targets
Anti-Cancer Agents in Medicinal Chemistry Predictions of the ADMET Properties of Candidate Drug Molecules Utilizing Different QSAR/QSPR Modelling Approaches
Current Drug Metabolism Genes of Human Longevity: An Endless Quest?
Current Vascular Pharmacology Cancer Stem Cells and their Management in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets Establishing Genomic/Transcriptomic Links Between Alzheimer’s Disease and Type 2 Diabetes Mellitus by Meta-Analysis Approach
CNS & Neurological Disorders - Drug Targets A Review on the Development in the Field of NIDDM based Thiazolidinedione PPARγ Agonists
Mini-Reviews in Medicinal Chemistry Ellipticines as DNA-Targeted Chemotherapeutics
Current Medicinal Chemistry Parathyroid Hormone Determination in Ultrasound-Guided Fine Needle Aspirates Allows the Differentiation between Thyroid and Parathyroid Lesions: Our Experience and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Subject Index to Volume 9
Current Pharmaceutical Design